The chemical compounds known to suppress the manifestations of rheumatic fever are reviewed and the antirheumatic nature of certain phenolic compounds discussed. We report on 75 patients with acute rheumatic fever who have been treated with gentisate compounds and discuss the records of 44 of these patients who have been followed for 3 to 20 months after discontinuing drug therapy. These patients were treated with sodium gentisate, "Gen," methyl cellulose-sodium gentisate and gentisic acid ethanolamide. The urinary excretion records of these drugs are given with selected blood level studies. The antihyaluronidase effect of salicylic acid metabolites and the relationship of these phenolic compounds to the pituitary-adrenal axis are discussed.
T HE chemical compounds known to suppress the manifestations of rheumatic fever are phenolic acid derivatives and the hormones cortisone and adenocorticotropic hormone (ACTH). These hormones have shed light on the pathogenesis of this disease but added little to our hope for better rheumatic fever therapy. Cortisone and adrenocorticotropic hormone are most effective in the severe form of acute rheumatic fever,31-2 but in general, their therapeutic results have been less satisfactory than those of salicylates 1 2, 5, 6, 8, 11, 12 ; the disease's manifestations recur when the hormones are stopped4 5 9, 10, 11 and the effect on carditis and valvular damage is of doubtful value.A2 The monophenolic salicylates continue to be regarded as the most generally effective and practically useful form of rheumatic fever therapy and can be used to differentiate rheumatic fever from other diseases which have similar symptomatology.
It is significant that since the salicylates were introduced 75 years ago,13 they have not been replaced in the treatment of rheumatic fever. The salicylates are but one of several phenolic
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The "Gen" used in this study was supplied through the courtesy of Edwin L. Gustus, Chicago, Ill., the gentisic acid ethanolamide by The Panray Corporation, New York City, the sodium gentisate tablets and sodium gentisate-methyl cellulose compound by Sutliff & Case Company, Inc., Peoria, Ill., and the Benemid by Sharpe & Dohme, Inc., Glenolden, Pa. 247 acid compounds that have antirheumatic properties. It has been demonstrated'4 that the monophenolic o-cresotinic acid is effective in rheumatic conditions, but others'5-'6 have found this drug inferior to the salicylates. The m-cresotinic acid has an effect similar to that of sodium salicylate.'6 A decoction of bilberry leaves, a constituent of which is the diphenolic hydroquinone, has been used in the treatment of rheumatism"7 and also the acetyl derivative of m-cresotinic acid or amatin,'8 which is tolerated by man up to 3 Gm. daily with good analgetic and antipyretic action and without it causing gastric irritation or marked perspiration. The drug salicyl resorcinol'9 has been used for the treatment of rheumatism, and acute rheumatic fever manifestations are suppressed by gamma resorcylic acid, but the meta and parahydroxybenzoic acids are inactive. 20 The phenolic compounds known to suppress some or all of the manifestations of rheumatic fever in the human have the following structures. 13 patients who had a primary attack of rheumatic fever. The drug was given for from 60 days to 6 months, with a starting schedule of 1.0 or 1.2 Gm. of sodium gentisate every three or four hours day and night. As improvement occurred, the amount of drug was gradually reduced to a minimum of 1.2 Gm. every four hours four times daily. Some of these patients obtained symptomatic relief within 24 hours after the sodium gentisate therapy was started, a few in four weeks, but most of these patients were symptom free within the first two weeks of treatment. Symptomatic relief occurred earlier in those patients who had the more severe form of rheumatic fever and who had the highest sedimentation rates. The temperature and heart rate became normal within two to three weeks and the sedimentation rate was normal in one to six weeks or in an average of four weeks. The only toxic reaction observed was nausea in two children, but when the sodium gentisate was given in a liquid vehicle the nausea promptly disappeared.
Monophenols
We have attempted to evaluate the degree of cardiac damage in these patients in whom gentisate treatment has been discontinued for from 3 to 15 months. Of 13 patients, a heart murmur was not heard in seven, and in 11 of these patients there was no evidence of heart enlargement; one patient had had a recurrence of rheumatic fever.
Fifteen patients who had a recurrent attack of rheumatic fever were given 5.2 to 10.4 Gm. of sodium gentisate every 24 hours, with most of them receiving 8.0 Gm. of the drug each day or 1.0 Gm. of sodium gentisate every three hours, day and night; this was decreased as improvement occurred. The drug was given for from 1 month to 24 months but most of these patients were treated for an average of six months. We found it necessary to continue sodium gentisate treatment for a longer time in the recurrent type of rheumatic fever, particularly in several patients who were in older age groups. Two of our patients with persistent rheumatic fever have required continuous therapy for 20 and 22 months to remain symptom free. There was complete relief of symptoms in from 24 hours to 3 weeks following sodium gentisate therapy with an average of 11 days. The blood sedimentation rate returned to normal in from 30 to 120 days with an average of 60 days for 13 of these patients. The disease manifestations have recurred in two of these patients, but 12 patients have remained symptom free for an average of eight months since sodium gentisate treatment was discontinued.
An attempt to evaluate increased cardiac damage in 13 patients after therapy had been discontinued for 3 to 20 months has shown the heart findings unchanged in six, the murmurs decreased in six, with an aortic diastolic murmur, previously present, absent in one; one patient has died.
We have found sodium gentisate to be more generally satisfactory than the salicylates in the treatment of the acute, recurrent and persistent forms of rheumatic fever, but it has two disadvantages. (1) Sodium gentisate is rapidly eliminated from the body, which requires that it be administered at frequent intervals throughout the entire day, and (2) the sodium content detracts from its use in patients with rheumatic heart disease and active carditis who are in a state of congestive heart failure. We have sought to overcome these defects of sodium gentisate in groups of patients treated with special compounds of gentisic acid.
Results of Treatment with "Gen"
Sodium gentisate was combined with a nonabsorbable, innocuous acid-absorbing resin to determine whether the speed of hydrolysis in the gastrointestinal tract could be retarded.
Such a combination, prepared under the trade name "Gen," was given to two patients who had primary attacks and to three patients who had recurrent attacks of rheumatic fever; the latter patients were in congestive heart failure. These patients received 1.0 to 1.2 Gm. of Gen every three or four hours day and night. In one patient who had a primary attack of rheumatic fever, the drug had to be discontinued after four weeks of therapy because of poor response. The second patient who had a primary attack of rheumatic fever required nine months of treatment with Gen before the rheumatic fever manifestations were suppressed. Of the three patients who had recurrent rheumatic fever and who were in congestive heart failure, one showed a minimal reduction in the rheumatic fever manifestations and gradual progression of the congestive heart failure, the Gen being discontinued after six weeks. The other two patients with congestive heart failure were relieved of their rheumatic fever manifestations, but they showed no corresponding improvement of their congestive heart failure which had to be corrected by digitalization and diuretics. The temperature, heart and sedimentation rates were influenced much more slowly with Gen than with sodium gentisate.
Our experience with Gen caused us to believe that this compound reduces the effect of sodium gentisate and that the use of an anion resin in combination with sodium gentisate does not improve the absorption of gentisic acid from the gastrointestinal system nor aid in the treatment of rheumatic fever patients who are in a state of congestive heart failure. In vitro studies with these tablets had demonstrated that disintegration in gastric and intestinal juices required twice the time for that of regular sodium gentisate tablets. Of six patients treated with methyl cellulose-sodium gentisate tablets, four had a primary and two a recurrent attack of rheumatic fever. Two of these patients were symptom free after four days of treatment, the maximum was two weeks and the average was one week. The sodium gentisate-methyl cellulose therapy was continued for from four weeks to three months, with all of these patients receiving 8.0 Gm. of methyl cellulose-sodium gentisate every 24 hours or 1.2 Gm. every three hours from 7 a.m. to 10 p.m. which avoided interrupting their sleep. The temperature of these patients became normal in an average of six days, and the heart rate was normal in an average of three weeks after therapy was instituted. The blood sedimentation rate became normal within 12 days to six weeks after methyl cellulosesodium gentisate treatment was started with an average of 28 days. There were no toxic reactions.
Results of
An attempt to evaluate heart damage three months after therapy had been discontinued showed the heart size normal in the four patients who had had primary attacks of rheumatic fever and the heart enlargement unchanged in the two patients who had had recurrent attacks of the disease. The heart murmurs persisted in all patients but in those who had primary attacks of rheumatic fever the murmurs were considerably decreased in intensity. Because of the sodium content, sodium gentisate-methyl cellulose is not satisfactory for patients who are in congestive heart failure but it does permit the use of smaller amounts of drug and it need be given less often, its action being more sustained with lower urinary minute output.
Results of Treatment with Gentisic Acid Ethanolamide
Five patients who had acute rheumatic fever were treated with gentisic acid ethanolamide. The ethanolamide of gentisic acid has been known for several years and has been used as a solubilizing agent for vitamins. No work had been done to evaluate this salt in the treatment of acute rheumatic fever. We were interested in its therapeutic possibilities but particularly for patients with acute rheumatic fever who were in congestive heart failure. Acute toxicity studies with gentisic acid ethanolamide in mice, rats and rabbits had shown that it was of much lower toxicity than was sodium salicylate. Chronic toxicity studies in young rats who received daily subcutaneous injections of gentisic acid ethanolamide in doses of 100 mg. per kilogram, and 300 mg. per kilogram, for four weeks, had shown no adverse influence on the growth rate or blood picture. The These five patients have been examined from four to five months after therapy was discontinued and all have shown a distinct reduction or change in the intensity and character of their former heart murmurs and the heart size has remained normal or unchanged. The state of congestive heart failure that was present in one of these patients was corrected with the suppression of the rheumatic fever, and a similar result has been observed in two other patients who have been followed for less than three months since the drug was discontinued. This limited experience suggests that gentisic acid ethanolamide has qualities which make it superior to sodium gentisate in the treatment of acute rheumatic fever. The gentisic acid ethanolamide therapy gave earlier symptomatic relief and the decline to normal of the temperature and pulse rate was more consistent and somewhat earlier than with sodium gentisate. The gentisic acid ethanolamide suppresses the manifestations of rheumatic fever with less drug than does sodium gentisate and the absence of sodium makes it desirable for patients who are in congestive heart failure.
Action on Lymphocytes
Of the 44 patients who had acute rheumatic fever and who were treated with compounds of gentisic acid, 39 had an average rise of 54 per cent and four patients had a distinct fall in their lymphocyte counts. The elevation of the lymphocyte counts occurred within the first 10 days after gentisate therapy had been started and later the lymphocyte counts gradually returned to their former or even lower levels. In some patients, and usually in the latter part of their illness, there was a secondary rise in the lymphocyte counts. An increase of 52 per cent in the lymphocyte count occurred within an average of nine days in 10 patients with acute rheumatic fever whom we treated with sodium salicylate.
Absolute Eosinophil Counts
Absolute eosinophil counts were obtained frequently on 23 patients. A more than 50 per cent decline in the absolute eosinophil count was observed in these patients within the first 10 days of gentisate therapy. In most of these patients the greatest decline in the absolute eosinophil count was observed on the sixth or seventh day of gentisate therapy. The absolute eosinophil count dropped from 250 and 800 eosinophil cells to zero cells in three patients after seven days of gentisate therapy and after nine days in another patient.
The Urinary Excretion of Gentisic Acid Compounds Chemically speaking the gentisates are derivatives of 2, 5-dihydroxybenzoic acid, and clinical experience had indicated that they were rapidly eliminated from the body. To determine the rates of elimination, the 24 hour urinary outputs were analyzed for the uncombined drug (table 1). The excretion of gentisic acid was not influenced by variations in the total urinary output unless the amount of urine was greatly limited. When this occurred, on the following day there was always an increased urinary output which compensated for the decrease of the previous day. The different urinary pH levels had no influence on the amount of gentisate excreted.
If we consider only the uncombined form of the drug, the ethanolamide of gentisic acid is excreted to a lesser extent than is the sodium gentisate or gentisic acid, a difference that is statistically significant, The excretion of gentisic acid ethanolamide in children is greater The adsorption of sodium gentisate on an anion resin does not decrease the amount of gentisate that is excreted through the urine in 24 hours. The same is true for the combination of sodium gentisate and methyl cellulose. The excretion of gentisic acid ethanolamide with Benemid in children and adults appears confusing, but we have tabulated only that portion of the drug that is excreted in the free or uncombined state. The apparent difference in excretion between the sodium gentisate and the gentisic acid ethanolamide is due to a greater conjugation of the latter compound. This ex- 
Blood Levels of Certain Gentisic Acid Compounds
The gentisic acid compounds suppress the manifestations of rheumatic fever at lower blood levels than are required for the salicylates. A blood level of 3.5 to 5 mg. of gentisic acid per 100 cc. is sufficient to suppress the manifestations of rheumatic fever. Table 4 gives the blood levels of patients receiving 1.0 Gm. of a gentisic acid compound every four hours with zero hour being just before the drug was given.
The combining of sodium gentisate with methyl cellulose retards the breakdown of the tablet in the gastrointestinal tract and produces a more constant and prolonged absorption of the gentisate into the blood stream as compared with the rapid and high absorption and rapid excretion which occurs with sodium gentisate and the limited absorption of sodium gentisate when combined with an anion resin. The total 24-hour urinary output of gentisate is the same for the three gentisate compounds.
We avoided the use of vitamin C with the gentisates so that we might obtain a single drug action on the rheumatic fever patient. This may account for some of the differences in our findings and those reported for other antirheumatic agents. DISCUSSION The metabolites of the salicylic acid are probably the substances which act to suppress the manifestations of rheumatic fever in patients receiving salicylate therapy. A mixture of the salicylic acid metabolite, gentisic acid, and hyaluronidase is inactive, but when such a mixture is incubated it becomes an active inhibitor of the depolymerization of hyaluronic acid by hyaluronidase.34 By means of the turbimetric method, it has been demonstrated35 that many other aromatic or phenolic compounds are inhibitors of hyaluronidase. The gentisic acid in the body is at least partially converted to the quinone form. It has been found by in vitro studies that the depolymerization of hyaluronic acid by hyaluronidase is inhibited by the quinone of gentisic acid or 2, 5-benzoquinone carboxylic acid at a concentration of 0.001 M and higher. 36 We have observed that an impure form of gentisic acid (90 per cent purity) was more effective in acute rheumatic fever patients than was a highly purified form of the drug. This is due to the presence of small amounts of the isomers of gentisic acid (side products of the synthesis of gentisic acid) or of the oxidized form of gentisic acid. The nonspecific hyaluronidase inhibitor in human serum appears to be a homogeneous complex of heparin, polypeptide and lipid which migrates with the albumin,37 while that which inhibits streptococcal hyaluronidase migrates entirely with the gamma globulin, is not heatlabile and is a true neutralizing antibody. 33 The known property of certain phenols to combine with or precipitate proteins and to block enzyme systems may account for their antihyaluronidase behavior and this ability varies with different phenolic compounds.
The antirheumatic action of salicylates and other phenolic derivatives may be mediated through the pituitary-adrenal axis and be more specific than has been formerly supposed. The specific action of certain phenolic compounds in rheumatic fever may be explained by the "accomplished ability to convert salicylic acid 'in vitro' to diphenic acid and thence to members of the steroid group and the direct action of salicylic acid upon cholesterol and/or cholesteryl esters to influence the concentration of the sterol and its esters and the ratio between the free cholesterol and the cholesteryl ester fraction" as suggested by Tormey and Barnhurst.39 The inherent inability of the rheumatic fever patient to demobilize the antihemolytic agent cholesterol after a hemolytic attack causes it to be partially demobilized abnormally through conversion to excess desoxycorticosterone.40 It has been shown that desoxycorticosterone can produce the characteristic changes of rheumatic fever.4'
The amount of ascorbic acid in the suprarenal glands is a measure of the glands' activity, and the removal of ascorbic acid from the adrenal gland is under the control of adrenocorticotropic hormone. The giving of preliminary treatment with the adrenal cortical hormone prevents the normal depletion of ascorbic acid by pituitary and adrenal gland activity. The agents which stimulate the adrenocorticotropic hormone-adrenocortical ac-24HENOLIC COMPOUNDS IN RHEUMATIC FEVER TREATMENT tivity probably do so by diminishing the concentration of the adrenal cortical hormone in the blood or by increasing its utilization by the tissues.42 It has been demonstrated in rats43 that salicylates cause a definite depletion of the ascorbic acid content of the adrenal glands, the degree of depletion being proportional to the amount of the drug that has been given. This response does not occur in hypophysectomized rats and tends to be inhibited by preliminary treatment with Cortone. In another study with rats,44 the subcutaneous injection of 400 mg. per kilogram of sodium salicylate produced a pronounced decrease in the ascorbic acid content of the pituitary and adrenal glands which persisted for more than 24 hours. The injection of 0.2 mg. of adrenaline (per rat) produced a similar but less marked effect.
There is a regular and increased excretion of reducing steroids but no regular effect on the excretion of the neutral 17-ketosteroids in humans with rheumatic diseases who are treated with acetyl salicylic acid, but there is no direct relationship between the amount of the reducing steroids excreted and the type of rheumatic disease but each increase in the excreted reducing steroids corresponds to the patient's clinical improvement.'5 A single intraperitoneal injection of a large dose of salicylate into intact rats produced the biochemical, histologic and hematologic picture of stress. After the injection of sodium salicylate into hypophysectomized rats, no significant change was observed in the ascorbic acid or cholesterol content of the adrenal glands nor was there an important decrease in the number of circulating eosinophils. Adrenocorticotropic hormone did produce significant biochemical and hematologic changes in the hypophysectomized rats similar to those observed in intact rats. 46 The integrity of the pituitary-adrenal axis may be essential for effective therapy with phenolic acid derivatives, and where adequate salicylate therapy has been ineffective, as in malignant rheumatic fever, perhaps the hypothalmic-pituitary-adrenal axis has been seriously damaged by the disease.
The reduction of circulating eosinophils by 50 per cent or more after the injection of a fixed amount of adrenocorticotropic hormone proves the integrity of the pituitary-adrenal axis. 47 The administration of salicylates produces a more than 50 per cent eosinopenia48 in guinea pigs and also in man.49 Others50 have been unable to demonstrate eosinopenia in normal humans in whom plasma salicylate concentrations, usually regarded as necessary, had been attained. A review"5 of this negative experience has shown that after a single oral dose of 4 or 6 Gm. of sodium salicylate there is no significant decrease in the absolute eosinophil count during the first four hours, but a significant drop occurs between the fourth and sixth hour due, undoubtedly, to the slow absorption from the intestinal tract. We have observed no important toxic reactions from the gentisates among the 75 patients whom we have treated, and we have given up to 6.0 Gm. in a single dose and as much as 5.2 Gm. a day for as long as 24 months. The two patients who received the drug in capsule form and who complained of nausea were given prompt relief when the gentisate was administered in a liquid vehicle.
SUMMARY
The general nature of phenolic acid compounds in the treatment of rheumatic fever has been discussed.
Of 75 patients treated with gentisate compounds, we have discussed 44 who have been observed for from 3 to 20 months after the drug had been discontinued.
The metabolism of salicylic acid in the human body and the therapeutic importance of its metabolites, and, in particular, of gentisic acid, have been reviewed.
The clinical and partial laboratory results have been presented for 28 patients who were treated with sodium gentisate, for five patients who were treated with a combination of sodium gentisate with an anion resin, for six patients who were treated with a combination of sodium gentisate and methyl cellulose and for five patients who were treated with gentisic acid ethanolamide.
It is our impression that gentisate compounds are more effective than other forms of rheumatic fever therapy in suppressing the manifestations of rheumatic fever.
The superior tolerance for the gentisates is impressive and makes the treatment of rheumatic fever easier for the doctor and the patient.
The methyl cellulose-sodium gentisate compound and gentisic acid ethanolamide showed slower absorption or utilization within the body and the sodium gentisate-methyl cellulose compound maintained the most constant therapeutic blood levels.
The gentisates cause a pronounced rise in the lymphocyte count rather than the reduced lymphocyte count observed with cortisone and adrenocorticotropic hormone therapy. We purposely chose to not use vitamin C in conjunetion with the gentisates so as to obtain a single drug response.
A relationship between salicylic acid or its metabolite, gentisic acid, and the corticoadrenal axis in acute rheumatic fever has been discussed.
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SUMARIO ESPANOL Los compuestos quimicos conocidos como supresores de las manifestaciones de la fiebre reumatica son revisados y la naturaleza antireumatica de ciertos compuestos fenolicos se discute. Se reporta sobre 75 pacientes con fiebre reumatica aguda que fueron tratados con compuestos gentisicos y se discute los records de 44 de los pacientes que han sido observados de 3 a 20 meses despues de la droga ser descontinuada. Estos pacientes fueron tratados con gentisato sodico. "Gen," metilo de celu losa-gentisato sodico y etanolamida de acido gentisico. La excrecion urinaria de estas drogas se informa con niveles de sangre seleccionados. El efecto antihialuronidasico del Acido salicilico y sus metabolitos y la relacion de los compuestos fenolicos al eje pituitario-adrenal se discute.
